Nuvation Bio (NYSE:NUVB) executives highlighted the company’s first full year of commercial activity for IBTROZI and outlined late-stage development plans for safusidenib during the company’s ...

About 1 in every 526 people in the U.S. will be diagnosed with chronic myeloid leukemia (CML) this year, but most of these people will achieve their normal life expectancy thanks to tyrosine kinase ...

Patients with acute lymphoblastic leukemia (ALL) who have an ABL-class fusion had better outcomes than a control group when treated with tyrosine kinase inhibitors at their first relapse, according to ...

A real-world study demonstrated better survival outcomes when an immunotherapy is combined with a tyrosine kinase inhibitor rather than another immunotherapy therapy for intermediate-risk renal cell ...